Phase 2 study of bevacizumab and irinotecan as second-line therapy in patients with advanced colorectal cancer previously treated with oxaliplatin and bavacizumab

ABSTRACT: Interventions: Bevacizumab+Irinotecan Bevacizumab: 10mg/kg d.i.v. day1 Irinotecan:150mg/m2 d.i.v.day1 to be repeated every 2 weeks Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Advanced Colorectal Cancer

PROVIDER: 2622484 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR